Business Description
Oncopeptides AB
ISIN : SE0009414576
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.38 | |||||
Equity-to-Asset | 0.24 | |||||
Debt-to-Equity | 2.22 | |||||
Debt-to-EBITDA | -0.52 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -32.76 | |||||
Beneish M-Score | -0.2 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 53.4 | |||||
3-Year EPS without NRI Growth Rate | 52.4 | |||||
3-Year FCF Growth Rate | 47.2 | |||||
3-Year Book Growth Rate | -58 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.92 | |||||
9-Day RSI | 49.93 | |||||
14-Day RSI | 46.12 | |||||
6-1 Month Momentum % | -27.04 | |||||
12-1 Month Momentum % | -37.74 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.52 | |||||
Quick Ratio | 4.46 | |||||
Cash Ratio | 3.86 | |||||
Days Sales Outstanding | 269.93 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10 | |||||
Shareholder Yield % | -28.75 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 103.06 | |||||
Operating Margin % | -722.73 | |||||
Net Margin % | -707.3 | |||||
FCF Margin % | -793.56 | |||||
ROE % | -139.95 | |||||
ROA % | -78.26 | |||||
ROIC % | -390.71 | |||||
ROC (Joel Greenblatt) % | -1243.4 | |||||
ROCE % | -94.98 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 10.38 | |||||
PB Ratio | 6.43 | |||||
Price-to-Tangible-Book | 6.43 | |||||
EV-to-EBIT | -1.31 | |||||
EV-to-EBITDA | -1.31 | |||||
EV-to-Revenue | 9.02 | |||||
EV-to-FCF | -1.14 | |||||
Price-to-Net-Current-Asset-Value | 16.91 | |||||
Earnings Yield (Greenblatt) % | -76.34 | |||||
FCF Yield % | -76.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Oncopeptides AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 35.22 | ||
EPS (TTM) (kr) | -1.967 | ||
Beta | -1.61 | ||
Volatility % | 83.85 | ||
14-Day RSI | 46.12 | ||
14-Day ATR (kr) | 0.135459 | ||
20-Day SMA (kr) | 3.220125 | ||
12-1 Month Momentum % | -37.74 | ||
52-Week Range (kr) | 2.89 - 7.634998 | ||
Shares Outstanding (Mil) | 126.91 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Oncopeptides AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Oncopeptides AB Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Oncopeptides AB Frequently Asked Questions
What is Oncopeptides AB(LTS:0RN4)'s stock price today?
When is next earnings date of Oncopeptides AB(LTS:0RN4)?
Does Oncopeptides AB(LTS:0RN4) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |